News Archive

News Archive - Page 14 of 30 - Real Endpoints

Jan 10, 2023

Real Endpoints’ top 10 market access predictions for 2023

The team at Real Endpoints took a quick break from advising clients to prognosticate on all things market access in 2023 and here are the results.

read full article ›

Jan 10, 2023

Real Endpoints CEO Jeff Berkowitz will be at J.P. Morgan Healthcare Conference 2023

Real Endpoints CEO Jeff Berkowitz is looking forward to connecting with clients and old friends to talk top trends and what's ahead in the realm of drug pricing and market access in 2023. To connect with Jeff, reach out through LinkedIn or send an email to info@realendpoints.com

read full article ›

Jan 10, 2023

Portfolio valuation in the aftermath of the IRA

So many insights in this piece that resonate with our own thought leadership. The inflation reduction act adds important new wrinkles to a product pricing strategy that companies need to address much earlier in the development cycle than they traditionally do.

read full article ›

Jan 10, 2023

Eisai’s press release on its pricing decision for Leqembi (lecanemab)

Eisa's press release on its pricing decision for Leqembi (lecanemab) is worth studying for so many reasons. From a communications perspective, this is a great example of how to get in front of what is sure to be a controversial topic - system affordability - and own the narrative.

read full article ›

Oct 11, 2022

Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy

The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLO

read full article ›

Aug 29, 2022

On rare drugs, is ICER at least partly right?

Thanks to a whole set of powerful incentives, starting with the Orphan Drug Act, biotech's pipeline is full of drugs for rare diseases. This phenomenon hasn't gone unnoticed by insurers or policy wonks given the historical costs of these therapies.

read full article ›

Apr 14, 2022

Real Endpoints will attend Asembia Summit 2022

If you are attending and want to discuss trends and best practices related to market access, innovative contracting, or patient support services, please reach out. We'd love to connect.

read full article ›

Apr 14, 2022

World Health Day 2022

Health is important today and every day, but too many do not have access or can’t afford it.

read full article ›

Apr 14, 2022

The Access to Prescription Digital Therapeutics Act of 2022

Market access and drug pricing are top topics for potential legislation in Congress right now.

read full article ›

Apr 14, 2022

National Doctor’s Day 2022

Tomorrow is #NationalDoctorsDay and, boy, is our debt high right now. If ever there was a moment to say thank you, this is it.

read full article ›